CoChat

A shear gradient-activated microfluidic device for automated monitoring of whole blood haemostasis and platelet function

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Accurate assessment of blood haemostasis is essential for the management of patients who use extracorporeal devices, receive anticoagulation therapy or experience coagulopathies. However, current monitoring devices do not measure effects of haemodynamic forces that contribute significantly to platelet function and thrombus formation. Here we describe a microfluidic device that mimics a network of stenosed arteriolar vessels, permitting evaluation of blood clotting within small sample volumes under pathophysiological flow. By applying a clotting time analysis based on a phenomenological mathematical model of thrombus formation, coagulation and platelet function can be accurately measured in vitro in patient blood samples. When the device is integrated into an extracorporeal circuit in pig endotoxemia or heparin therapy models, it produces real-time readouts of alterations in coagulation ex vivo that are more reliable than standard clotting assays. Thus, this disposable device may be useful for personalized diagnostics and for real-time surveillance of antithrombotic therapy in clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms10176

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The biomimetic haemostasis monitoring microdevice. (a) Diagram of the device with line drawings below showing the design of the accelerating (pre-stenosed), uniform width (stenosed) and decelerating (post-stenosed) regions of the microchannels. The central stenosed region contains 12 parallel lanes of 200-μm-wide and 75-μm-high channels that repeatedly turn 60° a few times in each channel (scale bar, 500 μm). (b) Schematic of the haemostasis monitor device and method. Human whole blood is pushed or pulled by a syringe through an inline pressure sensor that connects to the device via tubing, and used to determine micro-clotting time. Optionally, fluorescence microscopy of fibrinogen and platelets allows simultaneous monitoring of thrombus formation. (c) Photograph of three haemostasis monitoring devices formed in a single piece of PDMS mould on top of a standard glass slide (75 × 50 mm). (d) Graph showing results of computational modelling of blood flow through the device. The wall shear rate across the length of the entire device (pre-stenosed through stenosed and post-stenosed; from left to right) is shown for various inlet flow velocities (u=0.01–0.5 m s−1). (e) The computed wall shear gradients at the pre-stenosed (black circles) and post-stenosed (black squares) sections plotted against the mean wall shear at the stenosed section (line of linear regression (dotted line); goodness of fit, r2=0.99; average slope, 3.49 mm−1). This linear relationship corresponds to a blood vessel that comprises of ∼55% stenosis. (f) Representative fluorescent micrographs of pre-stenosed, stenosed, and post-stenosed regions of the same microfluidic device, showing fibrin (top, green) and adhered platelets (bottom, red) after perfusing blood through the device, containing heparin (0.25 IU ml−1), for 20 min (scale bar, 500 μm). (g) Scanning electron micrographs of a blood clot formed inside the device near the post-stenosed region shown at progressively higher magnifications (left to right; scale bar, 500, 50, 10, 5 and 1 μm) demonstrating the presence of fibrin networks containing trapped blood cells (3 images at left), including activated platelets (2 right images).
Figure 1 The biomimetic haemostasis monitoring microdevice. (a) Diagram of the device with line drawings below showing the design of the accelerating (pre-stenosed), uniform width (stenosed) and decelerating (post-stenosed) regions of the microchannels. The central stenosed region contains 12 parallel lanes of 200-μm-wide and 75-μm-high channels that repeatedly turn 60° a few times in each channel (scale bar, 500 μm). (b) Schematic of the haemostasis monitor device and method. Human whole blood is pushed or pulled by a syringe through an inline pressure sensor that connects to the device via tubing, and used to determine micro-clotting time. Optionally, fluorescence microscopy of fibrinogen and platelets allows simultaneous monitoring of thrombus formation. (c) Photograph of three haemostasis monitoring devices formed in a single piece of PDMS mould on top of a standard glass slide (75 × 50 mm). (d) Graph showing results of computational modelling of blood flow through the device. The wall shear rate across the length of the entire device (pre-stenosed through stenosed and post-stenosed; from left to right) is shown for various inlet flow velocities (u=0.01–0.5 m s−1). (e) The computed wall shear gradients at the pre-stenosed (black circles) and post-stenosed (black squares) sections plotted against the mean wall shear at the stenosed section (line of linear regression (dotted line); goodness of fit, r2=0.99; average slope, 3.49 mm−1). This linear relationship corresponds to a blood vessel that comprises of ∼55% stenosis. (f) Representative fluorescent micrographs of pre-stenosed, stenosed, and post-stenosed regions of the same microfluidic device, showing fibrin (top, green) and adhered platelets (bottom, red) after perfusing blood through the device, containing heparin (0.25 IU ml−1), for 20 min (scale bar, 500 μm). (g) Scanning electron micrographs of a blood clot formed inside the device near the post-stenosed region shown at progressively higher magnifications (left to right; scale bar, 500, 50, 10, 5 and 1 μm) demonstrating the presence of fibrin networks containing trapped blood cells (3 images at left), including activated platelets (2 right images).CC BY · PubMed Central
Figure 2 Mathematical formulation and empirical validation of clotting time. (a) Representative fluorescent micrographs of fibrin (green) deposited within the microchannel after blood containing heparin (0.75 IU ml−1) was perfused through the channel for 0, 25, 50 and 60 min at a shear rate gradient of 4,375 s−1 mm−1 (scale bar, 250 μm). (b) The fluorescence intensity of fibrin clot normalized by the maximum (black circles), showing a sigmoidal trend (dotted line, goodness of fit, R2=0.99; n=3 donors, 1 replicate per experiment) over time in the observed region. Due to sigmoidal thrombus growth, the pressure rise across the device (relative to the pressure at the initial time) will follow a two-parameter (Tg and Ts) exponential (reciprocal of sigmoid) trend. (c) A representative plot showing mathematical function to predict thrombus formation with Tg=30 min and Ts=45 min. Microfluidic clotting time (μCT) is average of Tg and Ts. (d,e) Representative graph showing empirical validation of the analytical model by varying heparin (d; 0, 0.1, 0.5 and 1 IU ml−1; labelled in different shades of grey) at a given shear rate gradient of 1,225 s−1 mm−1, and by varying shear rate gradient (e; 525;1,225;2,625 and 5,250 s−1 mm−1; labelled in different shades of grey) at heparin concentration of 0.5 IU ml−1. (goodness of fits for d and e are presented in Supplementary Table 1; three experiments were performed for every condition). (f,g) Graph showing empirical validation of μCT derived from the phenomenological analytical model, by varying the heparin concentration in the range of 0–1 IU ml−1 and perfusing blood at shear rate gradients of 1,225 s−1 mm−1 (black circles) and 4,375 s−1 mm−1, (grey circles) respectively (f; line of linear regression (dotted line); goodness of fit, R2=0.99 and 0.98, respectively; n=3 donors, 1 replicate per experiment); and by varying the shear gradient in the range 262–8,750 s−1 mm−1 and perfusing blood at heparin concentrations of 0.25 IU ml−1 (black circles) and 0.5 IU ml−1 (grey circles), respectively (g; exponential decay regression curve (dotted line); goodness of fit, R2=0.76 and 0.79, respectively; n=3 donors, 1 replicate per experiment).
Figure 2 Mathematical formulation and empirical validation of clotting time. (a) Representative fluorescent micrographs of fibrin (green) deposited within the microchannel after blood containing heparin (0.75 IU ml−1) was perfused through the channel for 0, 25, 50 and 60 min at a shear rate gradient of 4,375 s−1 mm−1 (scale bar, 250 μm). (b) The fluorescence intensity of fibrin clot normalized by the maximum (black circles), showing a sigmoidal trend (dotted line, goodness of fit, R2=0.99; n=3 donors, 1 replicate per experiment) over time in the observed region. Due to sigmoidal thrombus growth, the pressure rise across the device (relative to the pressure at the initial time) will follow a two-parameter (Tg and Ts) exponential (reciprocal of sigmoid) trend. (c) A representative plot showing mathematical function to predict thrombus formation with Tg=30 min and Ts=45 min. Microfluidic clotting time (μCT) is average of Tg and Ts. (d,e) Representative graph showing empirical validation of the analytical model by varying heparin (d; 0, 0.1, 0.5 and 1 IU ml−1; labelled in different shades of grey) at a given shear rate gradient of 1,225 s−1 mm−1, and by varying shear rate gradient (e; 525;1,225;2,625 and 5,250 s−1 mm−1; labelled in different shades of grey) at heparin concentration of 0.5 IU ml−1. (goodness of fits for d and e are presented in Supplementary Table 1; three experiments were performed for every condition). (f,g) Graph showing empirical validation of μCT derived from the phenomenological analytical model, by varying the heparin concentration in the range of 0–1 IU ml−1 and perfusing blood at shear rate gradients of 1,225 s−1 mm−1 (black circles) and 4,375 s−1 mm−1, (grey circles) respectively (f; line of linear regression (dotted line); goodness of fit, R2=0.99 and 0.98, respectively; n=3 donors, 1 replicate per experiment); and by varying the shear gradient in the range 262–8,750 s−1 mm−1 and perfusing blood at heparin concentrations of 0.25 IU ml−1 (black circles) and 0.5 IU ml−1 (grey circles), respectively (g; exponential decay regression curve (dotted line); goodness of fit, R2=0.76 and 0.79, respectively; n=3 donors, 1 replicate per experiment).CC BY · PubMed Central
Figure 3 Rapid platelet function analysis in vitro (a) Microfluidic clotting time (μCT) measured when the blood is perfused (shear rate gradient=1,225 s−1 mm−1) through a haemostasis monitoring microdevice coated with collagen (black bars, 100 μg ml−1) compared with bare surface (white bars), shown at two different heparin concentrations (0.25 IU ml−1 and 0.5 IU ml−1, respectively; *P<0.05, multiple t-tests, s.e.m.; n=3 donors, 2 replicates per experiment). (b) Representative fluorescent micrographs of pre-stenosed, stenosed and post-stenosed regions of the same collagen-coated microfluidic device (shear gradient, 4,375 s−1 mm−1), showing fibrin (top, green) and adhered platelets (bottom, red) after it occluded due to perfusion of recalcified citrated blood for 20 min (scale bar, 500 μm). (c) μCT measured for citrated blood containing different doses of an anti-platelet drug, abciximab (Reopro), when perfused through the device after recalcification (shear gradient, 4,375 s−1 mm−1; *P<0.05, one-way ANOVA, s.e.m.; n=3 donors, 2 replicates per experiment). (d) μCT measured from perfused recalcified citrated blood samples (shear gradient, 4,375 s−1 mm−1) of healthy donors (white bars) versus patients who take Aspirin and Plavix (clopidogrel) regularly (black bars) (*P<0.05, unpaired t-test, s.e.m.; n=5 healthy donors and 9 patients, 2 replicates per experiment). (e) A representative trace of pressure rise measured in the device, and fluorescent micrograph showing fibrin (top left,green) and platelet (top right,red) deposition at the post-stenosed region of the device, when blood from a healthy individual (H) was flowed through the device compared with blood from an HPS patient (P; shear gradient: 4,375 s−1 mm−1; scale bar: 500 μm). HPS, Hermansky–Pudlak Syndrome.
Figure 3 Rapid platelet function analysis in vitro (a) Microfluidic clotting time (μCT) measured when the blood is perfused (shear rate gradient=1,225 s−1 mm−1) through a haemostasis monitoring microdevice coated with collagen (black bars, 100 μg ml−1) compared with bare surface (white bars), shown at two different heparin concentrations (0.25 IU ml−1 and 0.5 IU ml−1, respectively; *P<0.05, multiple t-tests, s.e.m.; n=3 donors, 2 replicates per experiment). (b) Representative fluorescent micrographs of pre-stenosed, stenosed and post-stenosed regions of the same collagen-coated microfluidic device (shear gradient, 4,375 s−1 mm−1), showing fibrin (top, green) and adhered platelets (bottom, red) after it occluded due to perfusion of recalcified citrated blood for 20 min (scale bar, 500 μm). (c) μCT measured for citrated blood containing different doses of an anti-platelet drug, abciximab (Reopro), when perfused through the device after recalcification (shear gradient, 4,375 s−1 mm−1; *P<0.05, one-way ANOVA, s.e.m.; n=3 donors, 2 replicates per experiment). (d) μCT measured from perfused recalcified citrated blood samples (shear gradient, 4,375 s−1 mm−1) of healthy donors (white bars) versus patients who take Aspirin and Plavix (clopidogrel) regularly (black bars) (*P<0.05, unpaired t-test, s.e.m.; n=5 healthy donors and 9 patients, 2 replicates per experiment). (e) A representative trace of pressure rise measured in the device, and fluorescent micrograph showing fibrin (top left,green) and platelet (top right,red) deposition at the post-stenosed region of the device, when blood from a healthy individual (H) was flowed through the device compared with blood from an HPS patient (P; shear gradient: 4,375 s−1 mm−1; scale bar: 500 μm). HPS, Hermansky–Pudlak Syndrome.CC BY · PubMed Central
Figure 4 Ex vivo monitoring of coagulopathy and anticoagulation therapy in pigs. (a) Photograph showing a functioning microfluidic device attached to the femoral vein of a pig via a trilumen catheter. Blood is pulled at a set flow rate (shear gradient=4,375 s−1 mm−1) so that it passes through the device and the inline pressure sensor, forming clots inside the device; pressure data are automatically acquired on a laptop. (b–d) endotoxemic shock model. Lipopolysaccharide endotoxin (LPS) was infused into a pig over 1.5 h (grey shaded region, −1.5–0 h), and then thrombin-antithrombin (TAT) complexes in plasma (b; baseline=11.95 ng ml−1), fibrinogen concentration in plasma (c; baseline=143.61 ng ml−1), and microfluidic clotting time (μCT) calculated using the microchip (d; baseline=20.64 min; *P<0.05 compared with baseline, one-way ANOVA, s.e.m.) were measured every hour thereafter. (e) Pearson correlation coefficient (r) of aPTT (light grey), ACT (dark grey) and μCT (green) compared with TAT and fibrinogen measurements (n=3 pigs, 2 replicates per experiment). (f,g) Heparin therapy model. Fold change (relative to baseline at no heparin), in heparin concentration (black circles) measured by Factor Xa assay (f) and μCT (black circles) measured using the microfluidic haemostasis monitor (g) (baseline=4.25 min; full line, line of linear regression; dotted line, 95% confidence interval of the linear fit). (h) Graph showing the sensitivity of aPTT (light grey), ACT (dark grey) and μCT (green) assays (**P<0.01, one-way ANOVA, s.e.m.; n=3 pigs, 2 replicates per experiment).
Figure 4 Ex vivo monitoring of coagulopathy and anticoagulation therapy in pigs. (a) Photograph showing a functioning microfluidic device attached to the femoral vein of a pig via a trilumen catheter. Blood is pulled at a set flow rate (shear gradient=4,375 s−1 mm−1) so that it passes through the device and the inline pressure sensor, forming clots inside the device; pressure data are automatically acquired on a laptop. (b–d) endotoxemic shock model. Lipopolysaccharide endotoxin (LPS) was infused into a pig over 1.5 h (grey shaded region, −1.5–0 h), and then thrombin-antithrombin (TAT) complexes in plasma (b; baseline=11.95 ng ml−1), fibrinogen concentration in plasma (c; baseline=143.61 ng ml−1), and microfluidic clotting time (μCT) calculated using the microchip (d; baseline=20.64 min; *P<0.05 compared with baseline, one-way ANOVA, s.e.m.) were measured every hour thereafter. (e) Pearson correlation coefficient (r) of aPTT (light grey), ACT (dark grey) and μCT (green) compared with TAT and fibrinogen measurements (n=3 pigs, 2 replicates per experiment). (f,g) Heparin therapy model. Fold change (relative to baseline at no heparin), in heparin concentration (black circles) measured by Factor Xa assay (f) and μCT (black circles) measured using the microfluidic haemostasis monitor (g) (baseline=4.25 min; full line, line of linear regression; dotted line, 95% confidence interval of the linear fit). (h) Graph showing the sensitivity of aPTT (light grey), ACT (dark grey) and μCT (green) assays (**P<0.01, one-way ANOVA, s.e.m.; n=3 pigs, 2 replicates per experiment).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 186

Metadata

Authors
Jain, A., Graveline, A., Waterhouse, A., Vernet, A., Flaumenhaft, R., & Ingber, D. E.
Affiliations
  • Boston Children's Hospital (US)
  • Harvard University (US)
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
Ingber, Donald E.
Venue
Nature Communications
Published
2016-01-06
Volume
7
Issue
1
Pages
10176-10176
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2343360984
Cited by
182
References
47
Citations by year
2026: 8 · 2025: 16 · 2024: 20 · 2023: 18 · 2022: 12 · 2021: 14 · 2020: 28 · 2019: 22 · 2018: 15 · 2017: 18 · 2016: 11
FWCI
19.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Science Foundation (ECS- 03-35765, 0335765)
  • Harvard University (ECS-0335765)
  • National Institutes of Health (ECS-0335765)
  • Defense Advanced Research Projects Agency (N66001‐11‐1‐4180, HR0011, HR0011-13-C-0025)
  • Hansjörg Wyss Institute for Biologically Inspired Engineering, Harvard University
  • National Heart, Lung, and Blood Institute (R01HL125275, R01HL112809, T32HL007917)
Topics
  • Health Sciences › Medicine › Hematology › Blood properties and coagulation
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
platelet function, microfluidics, shear gradient, thrombus formation, coagulation, extracorporeal circuit, anticoagulation, heparin, endotoxemia, coagulopathy, personalized diagnosis
MeSH terms
Abciximab, Animals, Antibodies, Monoclonal, Blood Coagulation Tests, Blood Platelets, Female, Hemostasis, Humans, Immunoglobulin Fab Fragments, Platelet Aggregation, Platelet Aggregation Inhibitors, Platelet Function Tests, Swine, Point-of-Care Systems, Shear Strength, Microfluidic Analytical Techniques, Lab-On-A-Chip Devices

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.